CEO Mitchell Steiner highlighted Veru's transition to a pure-play late clinical stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases, following the divestiture of the ...

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...

In the combined Phase 3 VELA program, all endpoints reached statistical significance with p-values below 0.001, including lesion counts and patient reported outcomes (PROs), as per Table 2.

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic ...

Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in ...

Data from the Phase 2 and Phase 1 PK-LDI MariTide studies informed the Phase 3 MARITIME program. The recently initiated Phase 3, 72-week chronic weight management studies will evaluate the safety, ...

The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) GAITHERSBURG, Md., April 01, 2022 (GLOBE ...

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at ...